The effectiveness of Mexidol Correction in the correction of the post -shoe syndrome in patients with chronic cerebrovascular diseases

Authors:

E.B. Kuznetsova, E.A. Salina, N.S. Kuznetsov

FSBEI in "Saratov State Medical University named after V.I. Razumovsky "Ministry of Health of Russia, Saratov, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2023, Vol. 123, No. 5

Abstract:
Objective of the study. To evaluate the efficacy of sequential therapy with Mexidol and Mexidol FORTE 250 in the correction of post-COVID syndrome (PCS) in patients with chronic cerebrovascular diseases (CCVD). Material and methods. The results of examination and treatment of 110 patients with CCVD who had recovered from COVID-19 were analyzed. Patients of the main group (MG, n=55) received Mexidol (5 ml intravenously by drip for 14 days, followed by a transition to the tablet form of Mexidol FORTE 250, 1 tablet 3 times a day for 2 months); 55 patients of the comparison group (CG) did not receive antioxidants. All patients included in the study underwent MRI examination and comprehensive neuropsychological testing. Results. Patients in the MG showed a significant improvement in cognitive functions, regression of asthenia symptoms, and improved night sleep. The differences were statistically significant compared to both baseline and control. Conclusion. Mexidol administration does not require age-related dose adjustments and is well-suited for use with background therapy. The recommended regimen for Mexidol is 5 ml IV or IM for 14 days, followed by Mexidol FORTE 250 at a dose of 1 tablet 3 times daily for 2 months. Keywords: chronic cerebrovascular diseases, post-COVID syndrome, Mexidol, treatment.